A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial of sodium oligomannate for #br# mild-to-moderate Alzheimer disease

XIAO Shi-fu

PDF(194 KB)
中国药理学与毒理学杂志
PDF(194 KB)
中国药理学与毒理学杂志 ›› 2019, Vol. 33 ›› Issue (6) : 403-403.
大会报告

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial of sodium oligomannate for #br# mild-to-moderate Alzheimer disease

    {{javascript:window.custom_author_cn_index=0;}}
  • {{article.zuoZhe_CN}}
作者信息 +

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial of sodium oligomannate for #br# mild-to-moderate Alzheimer disease

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

本文亮点

{{article.keyPoints_cn}}

HeighLight

{{article.keyPoints_en}}

摘要

{{article.zhaiyao_cn}}

Abstract

{{article.zhaiyao_en}}

关键词

Key words

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
{{article.zuoZheCn_L}}. {{article.title_cn}}. {{journal.qiKanMingCheng_CN}}. 2019, 33(6): 403-403
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2019, 33(6): 403-403

参考文献

原文顺序 | 文献年度倒序 | 文中引用次数倒序

参考文献

{{article.reference}}

基金

版权

{{article.copyrightStatement_cn}}
{{article.copyrightLicense_cn}}
PDF(194 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉